FBR has the best analysts on the Street imho..TXMD TherapeuticsMD (TXMD ) initiated with a Outperform at FBR Capital; tgt $34
TXMD TherapeuticsMD (TXMD ) initiated with a Outperform at FBR Capital; tgt $34. Firm believes co is well positioned to change the manner in which women are treated with hormone replacement therapy. They believe the drug could be the only bio-identical hormone formulation approved by the FDA, and new drug compounding regulations may permit the capture of disproportionate market share. They also believe it is reasonable that TherapeuticsMD could establish a sales and marketing presence adequate to market the HRT products, but they are mindful that the size of the commercial opportunity may attract interest from other biopharma companies seeking exposure to a therapeutic space that could experience re-growth.